24 Oct 18
Toute la journée
Médicaments innovants – 16e appel à propositions

Public ciblé : entreprises, organismes publics de recherche…

Le 16e appel à propositions de l’Initiative Technologique Conjointe IMI2 est publié.

7 sujets sont ouverts (soumission en une seule étape) :

  • Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for tuberculosis (TB) that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
  • Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
  • Discover and progress novel assets with new mechanisms of action (one preNME for TB and one preNME for NTM) and biomarkers for TB and NTM infection
  • Determination of gepotidacin levels in tonsils and prostatic tissue
  • Infection site targeting, antibiotic encapsulated in nanoparticles for treating extracellular bacterial infections
  • Functional Ethionamide boosters: a novel combination for tuberculosis therapy
  • Intravenous treatments of serious infections (urinary tract infections), intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria.

Informations : https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-16